XML 172 R103.htm IDEA: XBRL DOCUMENT
v3.23.1

Goodwill and intangible assets (Details 4) - USD ($) $ in Millions | 12 Months Ended
--- | ---
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020
Intangible Assets other than Goodwill |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |
Impairment charge | $ (1,326.0) | $ (403.0) | $ (914.0)
Acquired research and development [member] |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |
Impairment charge | (917.0) | (350.0) |
Technologies |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |
Impairment charge | (15.0) | (17.0) |
Currently marketed products |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |
Impairment charge | (322.0) | (1.0) |
Other intangible assets |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |
Impairment charge | (72.0) | (35.0) |
Innovative Medicines | Votrient [member] | Currently marketed products |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |
Impairment charge | (900.0) | (1,300.0) |
Operating segments [member] | Innovative Medicines | Intangible Assets other than Goodwill |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |
Impairment charge | (1,299.0) | (367.0) | (768.0)
Operating segments [member] | Sandoz | Intangible Assets other than Goodwill |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |
Impairment charge | (25.0) | (28.0) | (141.0)
Operating segments [member] | Corporate | Intangible Assets other than Goodwill |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |
Impairment charge | (2.0) | (8.0) | (5.0)
Accumulated depreciation, amortisation and impairment | Innovative Medicines | Acquired research and development [member] |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |
Impairment charge | $ (0.6) | $ (0.2) | (0.5)
Accumulated depreciation, amortisation and impairment | Innovative Medicines | Votrient [member] | Acquired research and development [member] |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |
Impairment charge |  |  | $ (0.2)

X
- Definition Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table. + References No definition available. + Details
Name: | ifrs-full_DisclosureOfIntangibleAssetsLineItems
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of impairment loss recognised in profit or loss for intangible assets and goodwill. [Refer: Impairment loss recognised in profit or loss; Intangible assets and goodwill] + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 38 -IssueDate 2022-03-24 -Paragraph 118 -Subparagraph e -Clause iv -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118_e_iv&doctype=Standard -URIDate 2022-03-24 + Details
Name: | ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_IntangibleAssetsOtherThanGoodwillMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=nvs_AcquiredResearchAndDevelopmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_TechnologybasedIntangibleAssetsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=nvs_CurrentlyMarketedProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_OtherIntangibleAssetsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_VotrientMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SegmentsAxis=nvs_SandozMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SegmentsAxis=nvs_CorporateMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |